Compare AbbVie Inc (ABBV) vs Crowdstrike Holdings Inc (CRWD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Crowdstrike Holdings Inc — how do they compare? AbbVie Inc trades at $249.74 (market cap $441.94B), while Crowdstrike Holdings Inc trades at $222.06 (market cap $225.95B). The key difference: AbbVie Inc is the larger of the two by market cap, and AbbVie Inc pays a 2.77% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals.
| ABBV | CRWD | |
|---|---|---|
Market Cap | $441.94B | $225.95B |
Sector | Health | Technology |
52-Week High | $263.58 | $225.16 |
52-Week Low | $197.38 | $87.56 |
Enterprise Value | $506.19B | $222.22B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
CrowdStrike (CRWD) trades at $225.16, up 5.01% in the last session and near its all-time high. The stock exhibits strong technical momentum with bullish moving averages and is trading above key support at $222. Fundamentally, revenue growth remains robust, reaching $3.95 billion in 2025, though profitability is inconsistent with a net margin of -0.6%. Recent positive news includes being named a leader in IDC's MDR market assessment (Business Wire, August 11, 2026) and strong performance at industry events.
The outlook is positive given strong revenue growth and market leadership in cybersecurity, but the stock carries significant risk due to its extreme valuation multiples (P/E of 765) and intense competition. Investment appeal hinges on sustained high growth justifying the premium, while key risks include execution missteps and a broader market pullback.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →
